Evidence map›Paper›PMID 30421127›Full record

ArticleMolecular biology reports2019

Development of drug-loaded protein nanoparticles displaying enzymatically-conjugated DNA aptamers for cancer cell targeting.

Masayasu Mie, Rie Matsumoto, Yasumasa Mashimo, Anthony E G Cass, Eiry Kobatake

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy.Frontiers in cell and developmental biology · 2021
    Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Masayasu MieDepartment of Life Science and Technology, School of Life Science and Technology and Engineering, Tokyo Institute of Technology, 4259, Midori-ku, Nagatsuta, Yokohama, 226-8502, Japan.
Rie MatsumotoDepartment of Life Science and Technology, School of Life Science and Technology and Engineering, Tokyo Institute of Technology, 4259, Midori-ku, Nagatsuta, Yokohama, 226-8502, Japan.
Yasumasa MashimoDepartment of Life Science and Technology, School of Life Science and Technology and Engineering, Tokyo Institute of Technology, 4259, Midori-ku, Nagatsuta, Yokohama, 226-8502, Japan.
Anthony E G CassDepartment of Chemistry, Imperial College London, London, W12 0BZ, UK.
Eiry KobatakeDepartment of Life Science and Technology, School of Life Science and Technology and Engineering, Tokyo Institute of Technology, 4259, Midori-ku, Nagatsuta, Yokohama, 226-8502, Japan. kobatake.e.aa@m.titech.ac.jp.
Tokyo Institute of Technology · JPImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modification of protein-based drug carriers with tumor-targeting properties is an important area of research in the field of anticancer drug delivery. To this end, we developed nanoparticles comprised of elastin-like polypeptides (ELPs) with fused poly-aspartic acid chains (ELP-D) displaying DNA aptamers. DNA aptamers were enzymatically conjugated to the surface of the nanoparticles via genetic incorporation of Gene A* protein into the sequence of the ELP-D fusion protein. Gene A* protein, derived from bacteriophage ϕX174, can form covalent complexes with single-stranded DNA via the latter's recognition sequence. Gene A* protein-displaying nanoparticles exhibited the ability to deliver the anticancer drug paclitaxel (PTX), whilst retaining activity of the conjugated Gene A* protein. PTX-loaded protein nanoparticles displaying DNA aptamers known to bind to the MUC1 tumor marker resulted in increased cytotoxicity with MCF-7 breast cancer cells compared to PTX-loaded protein nanoparticles without the DNA aptamer modification.

Indexed as

Antineoplastic AgentsAptamers, NucleotideBreast NeoplasmsCell Line, TumorDrug CarriersDrug Delivery SystemsElastinFemaleHumansMCF-7 CellsNanoparticlesNeoplasmsPaclitaxelAntineoplastic AgentsAptamers, NucleotideDrug CarriersElastinPaclitaxelDNA aptamerDrug delivery systemElastin-like polypeptideEnzymatically conjugationProtein-based nanoparticle

Identifiers

PMID30421127
OpenAlexW2901830516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.